GRTX - Galera Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

120.8M

Cash

38.76M

Avg Qtr Burn

-11.39M

Short % of Float

7.20%

Insider Ownership

9.56%

Institutional Own.

46.38%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Avasopasem Manganese (GC4419) Details Head and neck cancer, Cancer	NDA Resubmission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avasopasem Manganese (GC4419) Details Lung cancer, Esophagitis, Non-small cell lung carcinoma	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avasopasem Manganese (GC4419) Details Infectious disease, COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rucosopasem Details Cancer, Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rucosopasem Details Pancreatic cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.